Hepatitis C Caring Ambassadors Program Newsletter

May 2004



In The News


Wrong, Pamela, there is a cure



Idenix Announces Data Presentations at the 2005 Digestive Disease Week Meeting  http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/04-28-2005/0003491648&EDATE=


Hepatitis C deal proposed: Haemophiliacs who contracted hepatitis C in the bad-blood saga have proposed a $170,000 Government compensation deal for each person affected



Treating children with chronic hepatitis C



Specific genes predicts which patients respond to Hep C treatment



Milk thistle does not reduce deaths from liver diseases, best studies find http://www.hbns.org/news/milkthistle05-02-05.cfm  


Recruitment completed for optimization trial of therapeutic Hepatitis C vaccine



Hepatitis C Caring Ambassadors Program Applauds Governor Kulongoski's Proclamation of May 2005 as Hepatitis Awareness Month in Oregon



Synovate Healthcare Launches a New Hepatitis C Syndicated Patient Audit in the USA

Hepatitis C Caring Ambassadors Program Launches Hepatitis C Awareness 2005 Campaign: 100,000 Letters to Congress
Hepatitis C: small molecules, big business
Festival raises money for Hepatitis C treatment
Pegasys(R) Findings Suggest New Approaches to Maximize Hepatitis C Therapy
Vertex says drug quickly treats hepatitis C
Human Genome Sciences Reports Results of Preclinical Study Comparing Anti-Viral Activity of Albuferon(TM) And Three Other Forms of Interferon Alpha Used to Treat Hepatitis C
HCV viraemia means poorer immune response to HAART
Chiron, Enanta sign hepatitis C agreement


(China) Hepatitis C detection kit developed by company in Hunan Province



Study shows Schering-Plough's hepatitis C treatment is superior



Benitec to Present Preclinical Data on Its Hepatitis C Virus Program at The American Society for Gene Therapy Meeting



Cluster of HCV and LGV identified amongst gay men in the Netherlands



Clinical Trials, Cohort Studies, Pilot Studies
Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Kamal SM, et al. Gut. 2005 Jun;54(6):858-66.
Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hezode C, et al. Hepatology. 2005 May 12; [Epub ahead of print]
Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (the HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases. Ramos-Casals M, et al. J Intern Med. 2005 Jun;257(6):549-57.                
Pilot study of interferon gamma for chronic hepatitis C. Soza A, et al. J Hepatol. 2005 Apr 26; [Epub ahead of print]
Prevalence of blood-borne pathogens in an urban, university-based general surgical practice. Weiss ES, et al. Ann Surg. 2005 May;241(5):803-7; discussion 807-9.
Analysis of aberrant somatic hypermutation (SHM) in non-Hodgkin's lymphomas of patients with chronic HCV infection. Libra M, et al. J Pathol. 2005 May;206(1):87-91.
Prolonged Time until Seroconversion among Hemodialysis Patients: The Need for HCV PCR. Schroeter M, et al. Intervirology. 2005 Jul-Aug;48(4):213-5.
Basic and Applied Science, Pre-Clinical Studies
A novel immunocompetent rat model of HCV infection and hepatitis. Wu GY, Konishi M, Walton CM, Olive D, Hayashi K, Wu CH. Gastroenterology. 2005 May;128(5):1416-23.
Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. Wilson JA, Richardson CD. J Virol. 2005 Jun;79(11):7050-8.
Continuous release of hepatitis C virus (HCV) by peripheral blood mononuclear cells and B-lymphoblastoid cell-line cultures derived from HCV-infected patients. Bare P, et al. J Gen Virol. 2005 Jun;86(Pt 6):1717-27.
T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. Kaplan DE, et al. Hepatology. 2005 May 24;41(6):1365-1375 [Epub ahead of print]
HIV/HCV Coinfection
Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. Bongiovanni M, et al. Int J Antimicrob Agents. 2005 May 3; [Epub ahead of print]
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index. Kelleher TB, et al. J Hepatol. 2005 Apr 25; [Epub ahead of print] 
A cluster of acute hepatitis C virus infection among men who have sex with men - results from contact tracing and public health implications. Gotz HM, et al. AIDS. 2005 Jun 10;19(9):969-974. 
Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. Antonucci G, et al. Clin Infect Dis. 2005 Jun 15;40(12):e101-9. Epub 2005 May 5.
Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Laguno M, et al. Antivir Ther. 2005;10(3):423-9. 
Determinants of Transplant Surgeons' Willingness to Provide Organs to Patients Infected with HBV, HCV or HIV. Halpern SD, Asch DA, Shaked A, Stock PG, Blumberg E. Am J Transplant. 2005 Jun;5(6):1319-25.
Complementary and Alternative Therapies
The effect of zinc supplementation on the treatment of chronic hepatitis C patients with interferon and ribavirin. Ko WS, et al. Clin Biochem. 2005 May 16; [Epub ahead of print]
Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C. Bandara P, et al. Liver Int. 2005 Jun;25(3):518-26.
Acupuncture for Substance Abuse Treatment in the Downtown Eastside of Vancouver. Janssen PA, Demorest LC, Whynot EM. J Urban Health. 2005 May 4; [Epub ahead of print]
Miscellaneous Works
Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. Gelatti U, et al. J Hepatol. 2005 Apr;42(4):528-34.     
Availability, safety and quality of blood for transfusion in the Americas. Cruz JR, Perez-Rosales MD. World Hosp Health Serv. 2005;41(1):25, 27-31.
Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon alpha-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. Siebert U, et al. Eur J Health Econ. 2005 May 18; [Epub ahead of print]
Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States. Hu KQ, et al. Int J Med Sci. 2004;1(2):92-100. Epub 2004 Jun 1.           
Hepatitis C virus seroprevalence and genotypes in patients with diffuse connective tissue diseases and spondyloarthropathies. Barbosa VS, Silva NA, Martins RM. Braz J Med Biol Res. 2005 May;38(5):801-5. Epub 2005 May 25.
Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Lackner C, et al. Hepatology. 2005 May 24;41(6):1376-1382 [Epub ahead of print]

Abstracts of interest:  DDW 2005

NOTE:  Abstracts of the meeting can be searched for and viewed at http://precis.preciscentral.com/Utils/ip/FindPresentation.asp?EventId=7cbbc409&bhcp=1  
Analysis Of Angiogenesis Soluble Factors (asf) in Chronic Hepatitis C (chc) Patients. Salcedo-Mora XB, et al. Presentation Number: S1560.
Interim Results From the PACT-Trial: High Antiviral Efficacy of Daily Consensus Interferon/ribavirin Compared to Peg-Interferon Alfa2b/ribavirin in Treatment-Naive Patients with Chronic Hepatitis C and Serotype-2 or -3. Bocher W, et al. Presentation Number: S1531
Baseline Fibrosis Score Does Not Predict Sustained Virological Response to Peginterferon Alfa-2a (40KD) Plus Ribavirin in Patients with Chronic Hepatitis C and Persistently ‘normal’ Alt Levels. Reindollar R, et al. Presentation Number: S1566


The Effect of Weight on Exposure in Hepatitis C: Peginterferon Alfa-2b and Peginterferon Álfa-2a. Silva M, et al. Presentation Number: S1570. 

A Pilot Study Of Etanercept Treatment for Inhibition Of Fibrotic Progression in Chronic Hepatitis C Infection. Marrero RJ, et al. Presentation Number: S1557.


Consensus Interferon (IFN Alfacon-1) Alone or in Combination With IFN Gamma-1b Suppresses Replication Of a PEG IFN-Alpha-2b--Resistant Hepatitis C Virus Replicon. Kaup A, et al. Presentation Number: S918.


High Dose Consensus Interferon and Ribavirin Is Effective for Treatment Of Chronic Hepatitis C Infection in Patients Who Are Resistant To Peg-Interferon and Ribavirin. Rothstein KD, et al. Presentation Number: S1536. 


Efficacy Of 24 Weeks of Treatment with Peginterferon Alfa-2b 1.5 µg/kg/week Plus Ribavirin 800-1400 Mg/day (p/r) in Patients Infected With Chronic Hepatitis C with Genotype 1 Of Low Viral Load (lvlg1). Zeuzem S, et al. Presentation Number: S1542


Treatment of Hepatitis C Among HIV/HCV Co-Infected Patients in the Veterans Administration (VA) System. Tam HK, et al. Presentation Number: S1573


Repetition of Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma and Prolongs the Long-Term Survival in Patients with Chronic Hepatitis C. Iyoda K, et al. Presentation Number: S1551


High Serum Leptin Is an Independent Risk Factor for Non-Response to Antiviral Treatment in Chronic Hepatitis C. Yatsuda M, et al. Presentation Number: S1581


The Impact of a Multi-Faceted Educational Intervention on the Knowledge of Primary Care Physicians Regarding Diagnosis, Evaluation, and Treatment of Hepatitis C Patients. Daniel AR, et al. Presentation Number: S930


Correlation Between Lipid Profile and Outcome of Hepatitis C Treatment. Gopal K, et al. Presentation Number: S1545


Virologic Response and Safety Outcomes in Therapy-Naive Patients Treated for Chronic Hepatitis C With Viramidine in Combination With Pegylated Interferon Alfa-2a. Gish RG, et al. Presentation Number: 2


Double-Dose Peginterferon Alfa-2b Plus Weight-Based Ribavirin for Re-Treatment of African-American Non-Responders with Hepatitis C. Gross JB, et al. Presentation Number: 87


Excessive Alcohol Consumption Is Associated With High Viral Load in Patients with Chronic Hepatitis C Infection. Cesario K, et al. Presentation Number: M1218


Role of CYP2D6 Polymorphism in Predicting Liver Fibrosis Progression Rate in Caucasian Patients with Chronic Hepatitis C. Fishman S, et al. Presentation Number: M955


Regression of Lymphoproliferative Disorders After Treatment for Hepatitis C Infection? a Systematic Review. Gisbert JP, et al. Presentation Number: M1031


Knowledge and Practices of Internal Medicine Residents in the Management of Chronic Hepatitis C (HCV) Infection: a Prospective Multicenter Survey. Lim JM, Ng JS, Proctor DD. Presentation Number: M1236.


Patient Knowledge of Hepatitis C Virus (HCV) Infection: a Comparison Between HCV-Infected Patients and HCV Negative Subjects. Shukla NB, et al. Presentation Number: M1239


Is Hepatitis C Virus Infection a Risk Factor for Diabetes Mellitus? Half a Million Us Veterans' Case-Control Study. Khurana v, et al. Presentation Number: M960


Clinical Utility Of Alpha Fetoprotein (AFP) L3 and Des-Gamma Carboxy Prothrombin (DCP) in Patients (pts) With Hepatitis C (HCV) and Advanced Fibrosis At Risk for Hepatocellular Carcinoma (HCC): Results From the Lead in Phase Of the HALT-C Trial. Sterling RK, et al. Presentation Number: M1670


Aspartate To Alanine Aminotransferase Ratio (AAAR) and Aspartate Aminotransferase To Platelets Ratio Index (APRI) As Non-Invasive Parameters for Predicting the Presence Of Significant Fibrosis in Patients With Chronic Hepatitis C. a Multi-Center Study. Giannini E, et al. Presentation Number: M957

The Impact Of Hepatitis C on Health Related Quality Of Life: a Systematic Review and Quantitative Assessment. Spiegel BM, et al. Presentation Number: M968
Outcome Of Hepatitis C Treatment in a Government-Sponsored Clinic for An Underserved Population. Iturrino J, et al. Presentation Number: W922